FAVO Capital Appoints Healthcare Executive Dr. Wael Barsoum to Board as Independent Director

FAVO Capital (OTC: FAVO), a diversified financial company with operations in financial services and real estate, has appointed Dr. Wael Barsoum to its board of directors as an independent director. Barsoum, former president and CEO of Cleveland Clinic Florida and current president and chief transformation officer at Healthcare Outcomes Performance Company, brings decades of leadership in healthcare innovation, governance, and organizational growth to the financial services firm.

The appointment reflects FAVO Capital's strategic focus on strengthening its governance structure with experienced leaders who can provide independent oversight and guidance. "Wael's appointment reflects our commitment to building a board with the independence, depth, and experience to guide FAVO's next chapter," said Shaun Quin, president of FAVO Capital. This move comes as the company continues to expand its operations across multiple business segments and geographic markets.

FAVO Capital operates across two primary segments: financial services and selective real assets. Through its financial services division, the company provides alternative, revenue-based funding solutions to small and mid-sized businesses across the United States. Since its inception, FAVO has supported more than 10,000 businesses through the purchase of future receipts, establishing itself as a significant player in the alternative lending space.

Complementing its lending platform, FAVO is building a portfolio of selective real assets that strengthen its balance sheet and broaden its collateral base. The company maintains operations in Florida, New York, and the Dominican Republic, with its headquarters located in Fort Lauderdale, Florida. Additional company information and updates are available in the company's newsroom at https://nnw.fm/FAVO.

The addition of Barsoum to the board signals FAVO's commitment to bringing diverse industry expertise to its leadership team. His background in healthcare innovation and organizational transformation could prove valuable as FAVO continues to evolve its business model and expand its market presence. The appointment of an independent director with Barsoum's credentials also enhances the company's corporate governance profile, which may be particularly important for investors monitoring the company's growth trajectory and management practices.

For investors seeking additional information about FAVO Capital and its recent developments, the full press release detailing Barsoum's appointment can be accessed at https://nnw.fm/gLEvl. The company has emphasized its commitment to financial transparency, sustainable growth, and long-term value creation for shareholders as it navigates the competitive financial services landscape.